Jeannette Lee
Concepts (472)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 22 | 2023 | 402 | 2.860 |
Why?
| | Anus Neoplasms | 10 | 2023 | 26 | 1.960 |
Why?
| | Stroke | 8 | 2024 | 520 | 1.800 |
Why?
| | Acquired Immunodeficiency Syndrome | 11 | 2022 | 53 | 1.470 |
Why?
| | Prostatic Hyperplasia | 10 | 2015 | 39 | 1.330 |
Why?
| | Brain | 10 | 2024 | 1353 | 1.300 |
Why?
| | Parkinson Disease | 2 | 2023 | 156 | 1.160 |
Why?
| | Chlamydia Infections | 8 | 2017 | 75 | 1.120 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2024 | 630 | 1.120 |
Why?
| | Papillomavirus Infections | 6 | 2022 | 177 | 1.060 |
Why?
| | Mesenchymal Stem Cell Transplantation | 2 | 2024 | 24 | 1.000 |
Why?
| | Sarcoma, Kaposi | 12 | 2022 | 77 | 0.970 |
Why?
| | Chlamydia trachomatis | 6 | 2017 | 29 | 0.940 |
Why?
| | Lymphoma, AIDS-Related | 10 | 2020 | 16 | 0.910 |
Why?
| | Brain Ischemia | 2 | 2023 | 162 | 0.830 |
Why?
| | Humans | 104 | 2026 | 53246 | 0.820 |
Why?
| | Plant Extracts | 5 | 2013 | 200 | 0.820 |
Why?
| | Serenoa | 5 | 2013 | 7 | 0.790 |
Why?
| | Phytotherapy | 3 | 2012 | 45 | 0.730 |
Why?
| | Rural Population | 4 | 2023 | 597 | 0.730 |
Why?
| | Umbilical Cord | 2 | 2020 | 36 | 0.720 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 1043 | 0.660 |
Why?
| | Lymphoma, Non-Hodgkin | 6 | 2021 | 58 | 0.660 |
Why?
| | Middle Aged | 50 | 2021 | 13422 | 0.650 |
Why?
| | Research Design | 5 | 2022 | 373 | 0.630 |
Why?
| | Neonatal Abstinence Syndrome | 3 | 2024 | 28 | 0.600 |
Why?
| | Male | 59 | 2024 | 27444 | 0.600 |
Why?
| | Adult | 50 | 2022 | 14541 | 0.590 |
Why?
| | Fetal Blood | 2 | 2019 | 79 | 0.590 |
Why?
| | Inflammation | 3 | 2021 | 653 | 0.570 |
Why?
| | Rats | 9 | 2024 | 3164 | 0.550 |
Why?
| | Patient Participation | 1 | 2018 | 72 | 0.540 |
Why?
| | Vaginosis, Bacterial | 2 | 2015 | 8 | 0.510 |
Why?
| | Decision Making | 1 | 2018 | 278 | 0.480 |
Why?
| | Antineoplastic Agents | 10 | 2023 | 1232 | 0.480 |
Why?
| | Neoplasms | 3 | 2023 | 1335 | 0.470 |
Why?
| | Mammography | 1 | 2016 | 99 | 0.470 |
Why?
| | Stem Cells | 3 | 2025 | 189 | 0.460 |
Why?
| | Female | 47 | 2024 | 28792 | 0.450 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 6 | 2015 | 46 | 0.440 |
Why?
| | Aged | 28 | 2020 | 10430 | 0.440 |
Why?
| | Infarction, Middle Cerebral Artery | 3 | 2024 | 41 | 0.430 |
Why?
| | Population Density | 1 | 2014 | 17 | 0.430 |
Why?
| | Pelvic Inflammatory Disease | 2 | 2018 | 8 | 0.430 |
Why?
| | AIDS-Related Opportunistic Infections | 5 | 2016 | 38 | 0.420 |
Why?
| | Animals | 15 | 2026 | 13528 | 0.420 |
Why?
| | Stem Cell Transplantation | 4 | 2025 | 191 | 0.420 |
Why?
| | Carcinoma in Situ | 3 | 2013 | 72 | 0.410 |
Why?
| | Cytokines | 5 | 2023 | 627 | 0.410 |
Why?
| | Uterine Cervicitis | 1 | 2013 | 3 | 0.390 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 832 | 0.390 |
Why?
| | Urethritis | 2 | 2012 | 5 | 0.380 |
Why?
| | Hydrocephalus, Normal Pressure | 1 | 2012 | 2 | 0.380 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 110 | 0.370 |
Why?
| | Finasteride | 4 | 2015 | 4 | 0.370 |
Why?
| | Research Subjects | 1 | 2013 | 53 | 0.360 |
Why?
| | Guideline Adherence | 1 | 2013 | 143 | 0.360 |
Why?
| | Breast Neoplasms | 3 | 2017 | 1223 | 0.360 |
Why?
| | Rats, Sprague-Dawley | 5 | 2024 | 1544 | 0.360 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2012 | 57 | 0.360 |
Why?
| | Patient Dropouts | 1 | 2012 | 52 | 0.350 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 175 | 0.340 |
Why?
| | Urologic Diseases | 1 | 2011 | 9 | 0.340 |
Why?
| | Homosexuality, Male | 4 | 2022 | 54 | 0.340 |
Why?
| | HIV-1 | 6 | 2020 | 60 | 0.330 |
Why?
| | Analgesics, Opioid | 4 | 2024 | 622 | 0.330 |
Why?
| | Lung Neoplasms | 2 | 2013 | 645 | 0.320 |
Why?
| | Disease Models, Animal | 5 | 2024 | 1517 | 0.320 |
Why?
| | Mitochondria | 3 | 2026 | 447 | 0.310 |
Why?
| | Young Adult | 17 | 2019 | 4514 | 0.310 |
Why?
| | Papillomaviridae | 3 | 2019 | 104 | 0.310 |
Why?
| | United States | 10 | 2023 | 5413 | 0.310 |
Why?
| | Quality of Life | 6 | 2024 | 902 | 0.300 |
Why?
| | Patient Selection | 1 | 2011 | 273 | 0.300 |
Why?
| | Lymphedema | 2 | 2022 | 48 | 0.290 |
Why?
| | HIV Seropositivity | 3 | 2021 | 28 | 0.290 |
Why?
| | Lower Urinary Tract Symptoms | 3 | 2013 | 7 | 0.290 |
Why?
| | Intestinal Mucosa | 2 | 2021 | 229 | 0.290 |
Why?
| | Asthma | 2 | 2024 | 319 | 0.290 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2017 | 505 | 0.280 |
Why?
| | Gonorrhea | 2 | 2020 | 9 | 0.270 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2022 | 301 | 0.270 |
Why?
| | Azithromycin | 4 | 2020 | 25 | 0.270 |
Why?
| | Anal Canal | 4 | 2023 | 27 | 0.260 |
Why?
| | Prospective Studies | 12 | 2022 | 2412 | 0.250 |
Why?
| | Risk Factors | 8 | 2022 | 4018 | 0.250 |
Why?
| | Th1 Cells | 2 | 2017 | 50 | 0.250 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2017 | 189 | 0.240 |
Why?
| | Huntington Disease | 1 | 2026 | 24 | 0.240 |
Why?
| | Mycoplasma genitalium | 2 | 2018 | 2 | 0.230 |
Why?
| | Doxazosin | 3 | 2015 | 3 | 0.230 |
Why?
| | Prevalence | 7 | 2021 | 1034 | 0.230 |
Why?
| | Treatment Outcome | 16 | 2020 | 5597 | 0.230 |
Why?
| | Mycoplasma Infections | 2 | 2018 | 7 | 0.230 |
Why?
| | Doxycycline | 3 | 2015 | 33 | 0.230 |
Why?
| | Cyclophosphamide | 9 | 2021 | 178 | 0.230 |
Why?
| | Cancer Vaccines | 1 | 2006 | 79 | 0.230 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 107 | 0.230 |
Why?
| | Vincristine | 8 | 2021 | 89 | 0.220 |
Why?
| | Adolescent | 13 | 2022 | 6912 | 0.220 |
Why?
| | Multicenter Studies as Topic | 4 | 2024 | 114 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2018 | 610 | 0.220 |
Why?
| | Circadian Rhythm | 1 | 2025 | 92 | 0.210 |
Why?
| | Air Filters | 1 | 2024 | 1 | 0.210 |
Why?
| | Double-Blind Method | 4 | 2013 | 729 | 0.210 |
Why?
| | CD4 Lymphocyte Count | 7 | 2020 | 33 | 0.200 |
Why?
| | Bronchiolitis | 1 | 2024 | 28 | 0.200 |
Why?
| | Air Pollution, Indoor | 1 | 2024 | 27 | 0.200 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2015 | 4 | 0.200 |
Why?
| | Hyperbaric Oxygenation | 1 | 2023 | 15 | 0.200 |
Why?
| | Neoplasm Staging | 5 | 2022 | 774 | 0.200 |
Why?
| | Cell Differentiation | 3 | 2025 | 681 | 0.200 |
Why?
| | Substantia Nigra | 1 | 2023 | 14 | 0.200 |
Why?
| | alpha-Synuclein | 1 | 2023 | 11 | 0.200 |
Why?
| | Doxorubicin | 8 | 2021 | 248 | 0.200 |
Why?
| | Cisplatin | 3 | 2022 | 282 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 392 | 0.190 |
Why?
| | Transplantation Conditioning | 2 | 2018 | 96 | 0.190 |
Why?
| | Informatics | 1 | 2023 | 9 | 0.190 |
Why?
| | Herpesvirus 8, Human | 5 | 2020 | 98 | 0.190 |
Why?
| | Prednisone | 7 | 2021 | 101 | 0.190 |
Why?
| | Follow-Up Studies | 8 | 2019 | 2318 | 0.190 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 1723 | 0.190 |
Why?
| | Astrocytes | 1 | 2024 | 139 | 0.190 |
Why?
| | Brachytherapy | 1 | 2022 | 51 | 0.180 |
Why?
| | Neuroprotective Agents | 2 | 2020 | 101 | 0.180 |
Why?
| | Watchful Waiting | 1 | 2022 | 29 | 0.180 |
Why?
| | Medical Records | 1 | 2022 | 85 | 0.180 |
Why?
| | Oxidative Phosphorylation | 1 | 2022 | 48 | 0.180 |
Why?
| | Feasibility Studies | 2 | 2021 | 412 | 0.180 |
Why?
| | Absorptiometry, Photon | 1 | 2003 | 161 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 168 | 0.180 |
Why?
| | Brain Injuries | 1 | 2023 | 160 | 0.180 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 46 | 0.180 |
Why?
| | Vaccines | 1 | 2022 | 49 | 0.180 |
Why?
| | Viral Load | 6 | 2020 | 83 | 0.180 |
Why?
| | Child | 7 | 2024 | 7384 | 0.180 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 184 | 0.180 |
Why?
| | Case-Control Studies | 3 | 2014 | 1212 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2022 | 87 | 0.170 |
Why?
| | Clinical Trials as Topic | 5 | 2020 | 466 | 0.170 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 163 | 0.170 |
Why?
| | Mouth Diseases | 1 | 2021 | 5 | 0.170 |
Why?
| | Mass Screening | 2 | 2015 | 362 | 0.170 |
Why?
| | Vaccination | 3 | 2022 | 310 | 0.170 |
Why?
| | Thymus Gland | 1 | 2021 | 39 | 0.170 |
Why?
| | Pluripotent Stem Cells | 1 | 2021 | 8 | 0.170 |
Why?
| | Progestins | 1 | 2020 | 10 | 0.170 |
Why?
| | T-Lymphocyte Subsets | 2 | 2017 | 39 | 0.160 |
Why?
| | Physical Conditioning, Animal | 1 | 2021 | 67 | 0.160 |
Why?
| | Drug Therapy, Combination | 5 | 2015 | 405 | 0.160 |
Why?
| | Primary Health Care | 2 | 2022 | 404 | 0.160 |
Why?
| | Vagina | 2 | 2018 | 45 | 0.160 |
Why?
| | Etoposide | 5 | 2021 | 71 | 0.160 |
Why?
| | Spleen | 1 | 2021 | 166 | 0.160 |
Why?
| | Papillomavirus Vaccines | 2 | 2013 | 74 | 0.160 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 371 | 0.160 |
Why?
| | Anti-HIV Agents | 3 | 2020 | 47 | 0.160 |
Why?
| | Cross-Over Studies | 1 | 2021 | 241 | 0.160 |
Why?
| | Genes, myc | 1 | 2020 | 39 | 0.160 |
Why?
| | Gene Frequency | 2 | 2017 | 97 | 0.160 |
Why?
| | Overweight | 1 | 2022 | 232 | 0.160 |
Why?
| | Transplantation, Autologous | 3 | 2018 | 488 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2013 | 3495 | 0.150 |
Why?
| | Nervous System Diseases | 1 | 2020 | 93 | 0.150 |
Why?
| | Dihydroxyphenylalanine | 1 | 2019 | 5 | 0.150 |
Why?
| | Dopaminergic Neurons | 1 | 2019 | 19 | 0.150 |
Why?
| | Ablation Techniques | 1 | 2019 | 19 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2024 | 2913 | 0.150 |
Why?
| | Genitalia, Male | 1 | 2019 | 16 | 0.140 |
Why?
| | Altruism | 1 | 2018 | 12 | 0.140 |
Why?
| | Sodium, Dietary | 1 | 2019 | 24 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2019 | 28 | 0.140 |
Why?
| | Mouth | 1 | 2019 | 36 | 0.140 |
Why?
| | Asymptomatic Infections | 1 | 2018 | 7 | 0.140 |
Why?
| | Dopamine | 1 | 2019 | 167 | 0.140 |
Why?
| | Antiviral Agents | 2 | 2013 | 179 | 0.140 |
Why?
| | Sexually Transmitted Diseases | 1 | 2018 | 37 | 0.140 |
Why?
| | Encephalitis | 1 | 2018 | 40 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2019 | 114 | 0.130 |
Why?
| | Chlamydia | 1 | 2017 | 8 | 0.130 |
Why?
| | Energy Metabolism | 1 | 2020 | 324 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2017 | 32 | 0.130 |
Why?
| | Biopsy | 2 | 2022 | 600 | 0.130 |
Why?
| | Regeneration | 1 | 2018 | 83 | 0.130 |
Why?
| | Pilot Projects | 3 | 2019 | 727 | 0.130 |
Why?
| | Blood Cells | 1 | 2017 | 37 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 533 | 0.130 |
Why?
| | Exosomes | 1 | 2018 | 58 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 234 | 0.130 |
Why?
| | DNA, Circular | 1 | 2017 | 17 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2018 | 56 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2017 | 29 | 0.130 |
Why?
| | Clonal Evolution | 1 | 2017 | 59 | 0.120 |
Why?
| | Immunoglobulins | 1 | 2017 | 76 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2017 | 192 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 233 | 0.120 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2017 | 119 | 0.120 |
Why?
| | Anus Diseases | 1 | 2016 | 2 | 0.120 |
Why?
| | Telemedicine | 1 | 2022 | 512 | 0.120 |
Why?
| | Lymph Node Excision | 1 | 2017 | 132 | 0.120 |
Why?
| | Mannitol | 1 | 2016 | 14 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2016 | 111 | 0.120 |
Why?
| | Thiazoles | 1 | 2016 | 52 | 0.120 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 7 | 0.120 |
Why?
| | Diagnostic Self Evaluation | 1 | 2015 | 13 | 0.120 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 51 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 1367 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 166 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2017 | 320 | 0.110 |
Why?
| | Educational Status | 1 | 2016 | 229 | 0.110 |
Why?
| | Tinidazole | 2 | 2012 | 2 | 0.110 |
Why?
| | Time Factors | 6 | 2023 | 2992 | 0.110 |
Why?
| | Imidazoles | 1 | 2016 | 114 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2017 | 252 | 0.110 |
Why?
| | Burkitt Lymphoma | 1 | 2015 | 27 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2020 | 370 | 0.110 |
Why?
| | Menarche | 1 | 2014 | 7 | 0.110 |
Why?
| | Data Collection | 3 | 2023 | 288 | 0.110 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2014 | 25 | 0.110 |
Why?
| | Obesity | 3 | 2022 | 1205 | 0.110 |
Why?
| | Stomatitis | 1 | 2014 | 19 | 0.110 |
Why?
| | Immunophenotyping | 2 | 2017 | 118 | 0.110 |
Why?
| | Disease-Free Survival | 5 | 2016 | 466 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 332 | 0.100 |
Why?
| | Benzamides | 1 | 2013 | 52 | 0.100 |
Why?
| | Hypogonadism | 1 | 2013 | 13 | 0.100 |
Why?
| | Incidence | 4 | 2018 | 1085 | 0.100 |
Why?
| | Urban Population | 1 | 2014 | 162 | 0.100 |
Why?
| | SEER Program | 1 | 2013 | 106 | 0.100 |
Why?
| | Health Surveys | 1 | 2014 | 248 | 0.100 |
Why?
| | Regenerative Medicine | 2 | 2025 | 12 | 0.100 |
Why?
| | Organophosphonates | 1 | 2013 | 6 | 0.100 |
Why?
| | Heart Failure | 1 | 2019 | 531 | 0.100 |
Why?
| | DNA, Viral | 3 | 2020 | 136 | 0.100 |
Why?
| | Perineum | 1 | 2013 | 26 | 0.100 |
Why?
| | Testosterone | 1 | 2013 | 142 | 0.100 |
Why?
| | Placebos | 1 | 2013 | 80 | 0.100 |
Why?
| | Cytosine | 1 | 2013 | 30 | 0.090 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2009 | 27 | 0.090 |
Why?
| | Piperazines | 1 | 2013 | 125 | 0.090 |
Why?
| | tau Proteins | 1 | 2012 | 25 | 0.090 |
Why?
| | Prostate | 2 | 2015 | 118 | 0.090 |
Why?
| | Trichomonas Infections | 1 | 2012 | 2 | 0.090 |
Why?
| | Trichomonas vaginalis | 1 | 2012 | 2 | 0.090 |
Why?
| | HIV | 3 | 2023 | 26 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 61 | 0.090 |
Why?
| | Pyrimidines | 1 | 2013 | 206 | 0.090 |
Why?
| | Sleep | 2 | 2024 | 196 | 0.090 |
Why?
| | Vulvar Neoplasms | 1 | 2013 | 61 | 0.090 |
Why?
| | Medicare | 1 | 2013 | 280 | 0.090 |
Why?
| | Urination Disorders | 1 | 2011 | 23 | 0.090 |
Why?
| | Androgen Antagonists | 1 | 2011 | 13 | 0.090 |
Why?
| | Comorbidity | 1 | 2013 | 638 | 0.090 |
Why?
| | Sirolimus | 1 | 2012 | 72 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2017 | 145 | 0.080 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 84 | 0.080 |
Why?
| | Kenya | 2 | 2022 | 11 | 0.080 |
Why?
| | Quinazolinones | 1 | 2011 | 7 | 0.080 |
Why?
| | Human papillomavirus 16 | 2 | 2013 | 44 | 0.080 |
Why?
| | Arkansas | 1 | 2016 | 2068 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 502 | 0.080 |
Why?
| | Social Class | 1 | 2011 | 97 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 598 | 0.080 |
Why?
| | Prognosis | 5 | 2017 | 2118 | 0.080 |
Why?
| | Chronic Disease | 1 | 2012 | 581 | 0.080 |
Why?
| | Piperidines | 1 | 2011 | 99 | 0.080 |
Why?
| | Plant Bark | 1 | 2009 | 4 | 0.080 |
Why?
| | Multiple Myeloma | 2 | 2014 | 3082 | 0.080 |
Why?
| | Valproic Acid | 1 | 2009 | 35 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2009 | 57 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 623 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 302 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 947 | 0.070 |
Why?
| | India | 2 | 2021 | 59 | 0.070 |
Why?
| | Fruit | 1 | 2009 | 129 | 0.070 |
Why?
| | Tetracyclines | 2 | 2006 | 9 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 647 | 0.070 |
Why?
| | Survival Analysis | 3 | 2017 | 659 | 0.070 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2015 | 32 | 0.070 |
Why?
| | Adaptive Immunity | 2 | 2017 | 32 | 0.070 |
Why?
| | Glioblastoma | 1 | 2009 | 101 | 0.070 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 50 | 0.060 |
Why?
| | Sexual Partners | 2 | 2018 | 45 | 0.060 |
Why?
| | Disease Progression | 4 | 2013 | 880 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2009 | 283 | 0.060 |
Why?
| | Regression Analysis | 2 | 2018 | 391 | 0.060 |
Why?
| | Chaperonins | 1 | 2006 | 3 | 0.060 |
Why?
| | Chaperonin 60 | 1 | 2006 | 6 | 0.060 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2006 | 13 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2006 | 20 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2017 | 975 | 0.060 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2006 | 30 | 0.060 |
Why?
| | Viral Vaccines | 1 | 2006 | 16 | 0.060 |
Why?
| | HIV Protease Inhibitors | 1 | 2006 | 3 | 0.060 |
Why?
| | Sexual Behavior | 2 | 2018 | 142 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2026 | 146 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 53 | 0.060 |
Why?
| | Infant | 2 | 2024 | 3808 | 0.060 |
Why?
| | Nephrosis, Lipoid | 1 | 2005 | 7 | 0.060 |
Why?
| | Arterioles | 1 | 2005 | 32 | 0.060 |
Why?
| | Body Mass Index | 2 | 2022 | 717 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2006 | 175 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2023 | 1049 | 0.060 |
Why?
| | Circadian Clocks | 1 | 2025 | 3 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2009 | 319 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2017 | 88 | 0.060 |
Why?
| | Administration, Oral | 4 | 2013 | 456 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2024 | 30 | 0.050 |
Why?
| | Phenotype | 2 | 2017 | 803 | 0.050 |
Why?
| | Anti-Retroviral Agents | 2 | 2019 | 18 | 0.050 |
Why?
| | Neutropenia | 2 | 2020 | 113 | 0.050 |
Why?
| | Genotype | 2 | 2017 | 563 | 0.050 |
Why?
| | Confidence Intervals | 2 | 2015 | 158 | 0.050 |
Why?
| | Dust | 1 | 2024 | 24 | 0.050 |
Why?
| | Particulate Matter | 1 | 2024 | 66 | 0.050 |
Why?
| | Carbon | 1 | 2024 | 60 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2023 | 78 | 0.050 |
Why?
| | Neurons | 1 | 2026 | 394 | 0.050 |
Why?
| | Femur Neck | 1 | 2003 | 6 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2006 | 349 | 0.050 |
Why?
| | Africa South of the Sahara | 1 | 2022 | 6 | 0.050 |
Why?
| | Hip | 1 | 2003 | 24 | 0.050 |
Why?
| | Oligomycins | 1 | 2022 | 8 | 0.050 |
Why?
| | Rotenone | 1 | 2022 | 13 | 0.050 |
Why?
| | Narcotics | 1 | 2023 | 108 | 0.050 |
Why?
| | Galactose | 1 | 2022 | 29 | 0.050 |
Why?
| | Quality Control | 1 | 2003 | 98 | 0.050 |
Why?
| | Eating | 1 | 2023 | 159 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 50 | 0.050 |
Why?
| | Breast Feeding | 1 | 2024 | 203 | 0.050 |
Why?
| | Femur | 1 | 2003 | 133 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 64 | 0.050 |
Why?
| | Spine | 1 | 2003 | 87 | 0.050 |
Why?
| | Mice | 2 | 2026 | 5982 | 0.040 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2002 | 9 | 0.040 |
Why?
| | Glycolysis | 1 | 2022 | 76 | 0.040 |
Why?
| | Tetracycline | 1 | 2002 | 24 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2022 | 249 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 91 | 0.040 |
Why?
| | Sodium | 1 | 2022 | 89 | 0.040 |
Why?
| | Tretinoin | 1 | 2002 | 53 | 0.040 |
Why?
| | Leg | 1 | 2022 | 123 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 477 | 0.040 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2017 | 35 | 0.040 |
Why?
| | Museums | 1 | 2021 | 2 | 0.040 |
Why?
| | Alprostadil | 1 | 2021 | 9 | 0.040 |
Why?
| | Ischemia | 1 | 2022 | 158 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 338 | 0.040 |
Why?
| | Progesterone | 1 | 2020 | 57 | 0.040 |
Why?
| | Kidney | 1 | 2005 | 717 | 0.040 |
Why?
| | Length of Stay | 1 | 2024 | 684 | 0.040 |
Why?
| | Zimbabwe | 1 | 2020 | 3 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 68 | 0.040 |
Why?
| | Software | 1 | 2003 | 280 | 0.040 |
Why?
| | Malawi | 1 | 2020 | 15 | 0.040 |
Why?
| | Wharton Jelly | 1 | 2020 | 2 | 0.040 |
Why?
| | Uganda | 1 | 2020 | 38 | 0.040 |
Why?
| | Spinal Cord Injuries | 1 | 2020 | 56 | 0.040 |
Why?
| | Cell Shape | 1 | 2020 | 21 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2020 | 44 | 0.040 |
Why?
| | Body Composition | 1 | 2003 | 355 | 0.040 |
Why?
| | Glucose | 1 | 2022 | 361 | 0.040 |
Why?
| | Neisseria gonorrhoeae | 1 | 2020 | 4 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 2020 | 57 | 0.040 |
Why?
| | Ceftriaxone | 1 | 2020 | 24 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2020 | 60 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2021 | 178 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2020 | 89 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 80 | 0.040 |
Why?
| | Interleukin-6 | 2 | 2016 | 272 | 0.040 |
Why?
| | Remission Induction | 2 | 2012 | 222 | 0.040 |
Why?
| | Proctoscopy | 1 | 2019 | 2 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 487 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 276 | 0.040 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2019 | 50 | 0.040 |
Why?
| | Forelimb | 1 | 2018 | 4 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 600 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 85 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2018 | 194 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2013 | 198 | 0.030 |
Why?
| | Models, Animal | 1 | 2019 | 233 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2017 | 12 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 595 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 238 | 0.030 |
Why?
| | Coinfection | 1 | 2018 | 41 | 0.030 |
Why?
| | Bone Marrow | 1 | 2019 | 359 | 0.030 |
Why?
| | Neurodegenerative Diseases | 1 | 2019 | 81 | 0.030 |
Why?
| | Postural Balance | 1 | 2018 | 59 | 0.030 |
Why?
| | Neurogenesis | 1 | 2017 | 29 | 0.030 |
Why?
| | Cell Separation | 1 | 2017 | 76 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 132 | 0.030 |
Why?
| | Cytological Techniques | 1 | 2017 | 13 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2017 | 69 | 0.030 |
Why?
| | Angiopoietin-1 | 1 | 2017 | 16 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2017 | 16 | 0.030 |
Why?
| | Axilla | 1 | 2017 | 92 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2017 | 17 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 48 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 94 | 0.030 |
Why?
| | Fluorouracil | 1 | 2016 | 59 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 76 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 567 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 181 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2017 | 238 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 174 | 0.030 |
Why?
| | Mastectomy | 1 | 2017 | 147 | 0.030 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 9 | 0.030 |
Why?
| | Directly Observed Therapy | 1 | 2015 | 5 | 0.030 |
Why?
| | Urine | 1 | 2015 | 26 | 0.030 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2015 | 16 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 158 | 0.030 |
Why?
| | Vaginal Smears | 1 | 2015 | 28 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 400 | 0.030 |
Why?
| | RNA, Viral | 2 | 2009 | 123 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 124 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 119 | 0.030 |
Why?
| | Prisons | 1 | 2015 | 40 | 0.030 |
Why?
| | Ifosfamide | 1 | 2015 | 9 | 0.030 |
Why?
| | Cytarabine | 1 | 2015 | 44 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 1587 | 0.030 |
Why?
| | Methotrexate | 1 | 2015 | 78 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2014 | 65 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 2 | 2006 | 58 | 0.030 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 19 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 34 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 1557 | 0.030 |
Why?
| | Depression | 1 | 2019 | 621 | 0.020 |
Why?
| | Melphalan | 1 | 2014 | 180 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 89 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 1003 | 0.020 |
Why?
| | Cancer Care Facilities | 1 | 2013 | 20 | 0.020 |
Why?
| | Time | 1 | 2013 | 28 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 53 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 211 | 0.020 |
Why?
| | Specialization | 1 | 2013 | 48 | 0.020 |
Why?
| | Demography | 1 | 2013 | 91 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 138 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 62 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 640 | 0.020 |
Why?
| | Antitrichomonal Agents | 1 | 2012 | 1 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 1368 | 0.020 |
Why?
| | Reference Values | 1 | 2013 | 311 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 95 | 0.020 |
Why?
| | Medical Oncology | 1 | 2013 | 97 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2012 | 44 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 62 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2011 | 120 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 330 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 228 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 747 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6821 | 0.020 |
Why?
| | Survival Rate | 1 | 2012 | 949 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2010 | 109 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2009 | 325 | 0.020 |
Why?
| | Mutation | 1 | 2013 | 1338 | 0.020 |
Why?
| | Busulfan | 1 | 2008 | 18 | 0.020 |
Why?
| | Psychometrics | 1 | 2009 | 244 | 0.020 |
Why?
| | Ultrasonography | 1 | 2008 | 426 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2006 | 42 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 55 | 0.010 |
Why?
| | Hypertension, Renal | 1 | 2005 | 21 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 1031 | 0.010 |
Why?
| | Fatigue | 1 | 2006 | 127 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 489 | 0.010 |
Why?
| | Receptors, Interleukin-6 | 1 | 2002 | 22 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 11 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 15 | 0.010 |
Why?
| | Lymphokines | 1 | 2002 | 20 | 0.010 |
Why?
| | Drug Tolerance | 1 | 2002 | 60 | 0.010 |
Why?
| | Safety | 1 | 2002 | 78 | 0.010 |
Why?
| | Child, Preschool | 1 | 2005 | 4164 | 0.010 |
Why?
|
|
Lee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|